Mereo BioPharma’s Post

Benchtop demonstration of XO Cath embolic compatibility. The 2.0F XO Cath is compatible with a full range of embolic agents and therapeutics, including 700um spheres and 500um particles. The XO Cath microcatheter has a minimal taper and an inner lumen size of 0.021". It is designed for controlled and selective infusion of diagnostic, embolic, or therapeutic materials into the peripheral vasculature. #interventionalradiology #interventionaloncology #embolization

🧠🔬Read the latest #LIOSpaper and learn how decreased long-chain #acylcarnitine content increases mitochondrial coupling efficiency and prevents ischemia-induced brain damage in rats. 📙 This #OpenAccess article is available in the journal "Biomedicine & Pharmacotherapy." Congratulations to the researchers team from the Laboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis! https://lnkd.in/d-QYe4R6

Benchtop demonstration of XO Cath microcatheter embolic compatibility. XO Cath is available in both 2.0F and 2.6F configurations and is compatible with a full range of embolic agents and therapeutics. The XO Cath microcatheter is designed for controlled and selective infusion of diagnostic, embolic, or therapeutic materials into the peripheral vasculature. #interventionalradiology #interventionaloncology #embolization

#VRCI In Nov’23, expert organ transplant diagnostics firm Verici Dx (Mrkcap £16m) signed a ground breaking global licensing deal with Thermo Fisher Scientific ($215bn Mrkcap) to exclusively develop an assay for pre-transplant kidney testing. #TMO’s assay is to be based directly on #VRCI’s patented Clarava blood test that allows doctors to identify those patients (pre graft) most likely to require increased monitoring (post operation)- including adjustments to the type, dose & duration of immunosuppressants. Elsewhere, the agreement also granted Thermo Fisher Scientific the sole right (but not obligation) to manufacture, distribute & sell the prognostic worldwide. Alongside providing it with access to a portion of #VRCI’s proprietary urine samples – further highlighting the value stored within its treasure trove of research assets. In return Verici Dx received an upfront fee, augmented by staged payments dependent on operational deliverables (eg tech transfer & publications). Which in aggregate (assuming things go to plan) should equate to c.$5m by Nov24 with further instalments & ongoing royalties thereafter. Today #VRCI said it had “completed successful transfer of a portion of the urine samples” and “full payment had been received”. Meaning this alongside the Jan’24 $6.5m fund raise, should extend the group's cash run-way into 2026. CEO Sara Barrington adding: "We are delighted to announce the successful completion of this transfer, within the agreed timeline. This achievement not only highlights our commitment to delivering on our agreements, but also underscores the substantial value inherent in Verici Dx's data and sample assets for research purposes." Looking ahead, Singer Capital Markets have a target price of 20p/share and are forecasting sales to jump to $7.5m and $13.0m this year and next (vs $1.0m LY), with #VRCI also becoming profitable in 2025 ($1.3m EBITDA). Disclosure: Verici Dx are a Vox Markets client

In a trial led by Ali Rezai, MD, from West Virginia University, a new method combining Aducanumab (Aduhelm) infusions with focused ultrasound showed promise in lowering amyloid-beta levels in Alzheimer's disease. The treatment involves using MRI-guided focused ultrasound to open the blood-brain barrier, enhancing drug delivery. Three patients who received Aducanumab infusions showed greater reduction in amyloid in brain regions targeted with focused ultrasound compared to regions without exposure to it. PET scans indicated a drop in amyloid levels in these targeted areas over 26 weeks, showcasing a potential 32% reduction in standardized uptake value ratio. However, there were some side effects reported. Headaches were the most common, mostly mild, except for one moderate case. Additionally, discomfort during ultrasound treatment led to two severe adverse events for one participant, quickly resolved after the procedure. No amyloid-related imaging abnormalities were observed. This method, which temporarily opens the blood-brain barrier, has shown success in various neurological conditions, and previous studies hinted at reduced amyloid-beta levels without therapeutic agents like Aducanumab. Though the trial's scale was limited to three patients and one side of the brain, larger trials exploring both brain sides are deemed crucial for further understanding and efficacy determination. Despite this, the findings fuel optimism that this approach combined with amyloid-beta removal agents could potentially slow Alzheimer's progression. #Aducanumab #AlzheimersResearch #FocusedUltrasound #endalz https://lnkd.in/gKuHNaK3

Comprehensive review covers chemical modification aiming at optimizing therapeutic efficacy of oligonucleotide sequences and in depth analysis of current delivery platforms #oligotherapeutics #RNA #delivery

New featured CE! 🔗 https://bit.ly/4e8RVmL The blood-brain barrier (BBB) remains a significant blockade for effective drug delivery in treating diffuse intrinsic pontine glioma (DIPG). Low-frequency focused ultrasound (FUS) therapy in conjunction with intravenous microbubbles can transiently disrupt the BBB in a localized manner to facilitate drug delivery. This review examines recent preclinical studies evaluating the safety and feasibility of FUS-mediated BBB opening in the brainstem. #CME #MedEd #RadEd

"In this manuscript, we demonstrate for the first time that a PolySialic Acid-Coated Nanoparticle (PolySia-NP) formulation regulates disease-associated inflammatory complement activity,” says Sheri Peterson, PhD, Sr. Scientist, Neurosciences, at Aviceda Therapeutics. “Alongside our recent work showing PolySia-NP–mediated resolution of disease-associated pro-inflammatory macrophages, these new findings support our ongoing clinical trials of PolySia-NPs for GA/AMD and our pre-clinical programs." You can read the piece that Dr. Peterson and colleagues published in the journal Pharmaceuticals here: https://lnkd.in/e-GTJsRV

𝗔𝗿𝗲 𝘆𝗼𝘂 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗰𝗮𝗿𝗱𝗶𝗮𝗰 𝗺𝗼𝗱𝗲𝗹𝘀 𝗳𝗼𝗿 𝗽𝗿𝗲-𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝘀𝘀𝗮𝘆𝘀? 𝗗𝗼𝗻’𝘁 𝗺𝗶𝘀𝘀 𝘁𝗵𝗲 𝘀𝗲𝗰𝗼𝗻𝗱 𝗲𝗱𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝗟𝗮𝗯𝗜𝗡𝗔𝗥 𝗕𝗥𝗘𝗔𝗞 Join Dr. Ravi Vaidyanathan from FUJIFILM Cellular Dynamics, Inc for an enlightening webinar hosted by innoVitro. The webinar will explore how 2D and 3D co-culture systems enhance the relevance of these cell models, bridging the gap between lab research and clinical success. Here’s why you should attend: 🌱 Introduction to iCell cardiac fibroblasts: These high-purity cells exhibit low lot-to-lot variability and express specific markers like POSTN, TE7, and Cx43. 🧪 Enhanced co-culture models: Learn about co-culturing iCell Cardiomyocytes² with iCell Cardiac Fibroblasts and/or endothelial cells in 2D and 3D systems, providing advanced models for preclinical screening assays. If you're a researcher in cardiac physiology, drug discovery, or regenerative medicine, this webinar is for you. Make sure to save your spot! 🔗 Register here: https://lnkd.in/dht5JBxB #Cardiac #Fibroblasts #DrugDevelopment #PreclinicalResearch #HumanCellModels #Pharmaceuticals #Cardiomyocytes

Today, Lineage Cell Therapeutics announces the submission of an Investigational New Drug amendment (INDa) to the FDA for OPC1, its investigational allogeneic oligodendrocyte progenitor cell transplant, for the treatment of spinal cord injury (SCI). Receipt of FDA clearance of the INDa would enable the Company to initiate its DOSED clinical study, to evaluate the safety and utility of a novel spinal cord delivery device in both subacute and chronic SCI patients. The OPC1 cell transplant is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from traumatic cervical or thoracic SCIs. Learn more: https://bit.ly/482gMFo #OPC1 #SCI #SpinalCord #ReplaceandRestore SCI Investor Symposium, California Institute for Regenerative Medicine (CIRM)